ABVX
Abivax S.A.Healthcare·Biotechnology
$132.63
$8.7B market cap
Revenue
$0.0M
Free Cash Flow
$-75.1M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops A
2-Year Price History
$121.99+771.4%
Quarterly Financials & Projections
Quarterly Waterfall (EUR M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2025-Q4 | 0.0 | -60.6 | -199.6 | -287.7 | -71.3 | -75.1 | -0.0 | 530.2 | 32.1 | 69.5 | -221.8% | -4.0x | -- |
Valuation & Metrics
Market Stats
Price$132.63
Market Cap$8.7B
Enterprise Value$7.0B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-1.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-287.7M
Free Cash Flow$-75.1M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-221.8%
WC Change % Rev0.0%
Interest Coverage-4.0x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.6M
Days to Cover3.2
Change (vs Prior)-0.6%
Need at least 2 settlement dates for chart
Employees
Headcount69
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
67.2%(+64.7% YoY)
237 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.7%(+0.7% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
0.8%(+0.8% YoY)
11 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| TCG Crossover Management, LLC | $722M | $23.46 | −$70.2M | +$47.3M | +3.0% | $3.50B |
| UBS Group AG | $506M | $82.57 | +$13.8M | +$488M | -0.3% | $562.11B |
| Darwin Global Management, Ltd. | $352M | $87.31 | +$32.3M | +$352M | -1.9% | $1.19B |
| MORGAN STANLEY | $190M | $96.80 | −$161M | +$134M | -0.3% | $1.65T |
| Vestal Point Capital, LP | $167M | $108.56 | −$44.5M | +$167M | -0.1% | $3.58B |
| Caligan Partners LP | $163M | $7.69 | +$1.1M | +$21.5M | +5.0% | $1.41B |
| ADAR1 Capital Management, LLC | $155M | $10.42 | +$8.5M | −$90.9M | +4.5% | $1.64B |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $147M | $129.29 | +$34.8M | +$147M | +2.7% | $23.59B |
| FMR LLC | $143M | $83.10 | −$8.8M | +$143M | -0.0% | $1.89T |
| Helikon Investments Ltd | $113M | $111.35 | +$113M | +$113M | +6.0% | $2.65B |
| Eversept Partners, LP | $104M | $105.10 | +$30.8M | +$104M | -0.4% | $1.52B |
| JANUS HENDERSON GROUP PLC | $98.0M | $46.82 | +$23.5M | +$98.0M | +1.2% | $209.29B |
| BAKER BROS. ADVISORS LP | $97.5M | $84.90 | +$0 | +$97.5M | -0.5% | $16.13B |
| LORD, ABBETT & CO. LLC | $95.2M | $115.03 | +$578K | +$95.2M | +0.4% | $30.58B |
| Paradigm Biocapital Advisors LP | $86.0M | $84.90 | −$71.8M | +$86.0M | +1.8% | $4.69B |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $85.3M | $87.33 | +$8.2M | +$85.3M | -0.2% | $1.18B |
| Cormorant Asset Management, LLC | $84.6M | $10.70 | −$65.7M | −$153M | -3.5% | $1.95B |
| BANK OF AMERICA CORP /DE/ | $81.9M | $119.95 | +$23.8M | +$80.7M | -0.1% | $1.36T |
| PRICE T ROWE ASSOCIATES INC /MD/ | $77.0M | $98.84 | +$4.5M | +$77.0M | -0.2% | $864.93B |
| Octagon Capital Advisors LP | $75.4M | $9.73 | −$8.8M | −$61.6M | -0.0% | $904M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+1.29%
avg per quarter
Holders (ex-self)
+0.67%
excl. this stock
Buyers (this Q)
+2.30%
110 buyers · $0.36B in
Sellers (this Q)
+0.54%
80 sellers · $1.78B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-4.4%
how holders react when this stock falls
On quiet Qs
-17.0%
−10% to +10% baseline
On rallies (+10%+)
-14.5%
how they react when this stock rises
Holders' portfolio flow this Q
+4.6%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.1%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.9%
Holder mid (any stock)
-0.7%
Holder rally (any stock)
-6.5%
Biggest decreases this quarter
Point72 Asset Management, L.P.−$197Mα+0.9MORGAN STANLEY−$161Mα-0.3DEUTSCHE BANK AG\exited−$103MParadigm Biocapital Advisors LP−$71.8Mα+1.8TCG Crossover Management, LLC−$70.2Mα+3.0BVF INC/ILexited−$68.5MCormorant Asset Management, LLC−$65.7Mα-3.5Frazier Life Sciences Management, L.P.exited−$51.0MVestal Point Capital, LP−$44.5Mα-0.1MILLENNIUM MANAGEMENT LLC−$15.0Mα-0.5
New buyers this quarter
Top-5 holders · 35.0%
TCG Crossover Management, LLC--
UBS Group AG--
Darwin Global Management, Ltd.--
MORGAN STANLEY--
Vestal Point Capital, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
TCG Crossover Management, LLC6.5MUBS Group AG4.5MDarwin Global Management, Ltd.3.5MMORGAN STANLEY1.7MPoint72 Asset Management, L.P.638KVestal Point Capital, LP1.5MCaligan Partners LP1.5MParadigm Biocapital Advisors LP772KFMR LLC1.3MCormorant Asset Management, LLC760K
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | 8 | 82.89× |
| BLTE | Belite Bio, Inc | 3 | 77.71× |
| AVR | Anteris Technologies Global Corp. | 3 | 77.71× |
| RAPP | Rapport Therapeutics, Inc. Common Stock | 3 | 77.71× |
| DNTH | Dianthus Therapeutics, Inc. | 13 | 77.71× |
| IVA | Inventiva S.A. | 5 | 70.64× |
| TYRA | Tyra Biosciences, Inc. | 6 | 66.61× |
| KOD | Kodiak Sciences Inc. | 5 | 64.76× |
| CELC | Celcuity Inc. | 8 | 62.17× |
| LBRX | LB Pharmaceuticals Inc Common Stock | 3 | 58.28× |
| VKTX | Viking Therapeutics, Inc. | 3 | 58.28× |
| SRRK | Scholar Rock Holding Corporation | 7 | 57.26× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$110.00-1710.0%
Last Year (14 analysts)$128.71-300.0%
Current Price$132.63
Analyst Ratings
9
Buy: 9Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
17.9%retail-3.5pp
27.5%dark+1.9pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Abivax SA: Clinical Breakthrough Purchased with Shareholder Erasure and Technical Insolvency
Overall Risk
8/10
Fraud
3/10
Dilution
9/10
Insolvency
7/10
Earnings Overstated
4/10
Hidden Liabilities
6/10
Legal
6/10
Audit Warnings
8/10
Hidden Upside
7/10
Contextually Acceptable
4/10